Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Clinicopathologic Conference, Acute human immunodeficiency virus type 1
NEJM 385:641-648, Case 24-2021, 2021
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Clinical Findings and Diagnosis in Human Granulocytic Anaplasmosis: A Case Series from Massachusetts
Mayo Clin Proc 87:233-239, Weil, A.A.,et al, 2012
The Neurologic Manifestations of Systemic Lupus Erythematosus
The Neurologist 15:115-121, Greenberg,B.M., 2009
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Antiepileptics and Blood Dyscrasias: A Cohort Study
Pharmacotherapy 18:1277-1283, Blackburn,S.C.F.,et al, 1998
Complications of Intravenous Immune Globulin Treatment in Neurologic Disease
Neurol 47:674-677, Brannagan III,T.H.,et al, 1996
Chronic Systemic High-Dose Recombinant Interferon Alfa-2a Reduces Exacerbation Rate & MRI Signs in MS
Neurol 44:406-413, Durelli,L.,et al, 1994
A Critical Appraisal of Ticlopidine, A New Antiplat Agent, Effectiveness & Clin Indic for Prophylaxis
Arch Int Med 152:1376-1380, Haynes,R.B.,et al, 1992
Carbamazepine-Induced Antinuclear Antibodies & Systemic Lupus Erythematosus-Like Syndrome
Epilepsia 32:128-129, DeGiorgio,C.M.,et al, 1991
Wilson Disease:Clinical Presentation, Treatment, and Survival
Ann Int Med 115:720-726, Stremmel,W.,et al, 1991
Recurrent Aseptic Meningitis in an Elderly Male, Unusual Prodromal Manifestation of SLE
JAMA 235:1142, Finelli,P.F.,et al, 1975